64. Thrombotic thrombocytopenic purpura Clinical trials / Disease details

Clinical trials : 92 / Drugs : 85 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 76

33 trials found

diseases per page:

Showing 1 to 10 of 33 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05468320 (ClinicalTrials.gov)	November 21, 2022	18/7/2022	Caplacizumaband Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults Wi ...	An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumaband ...	Thrombotic Thrombocytopenic Purpura	Drug: Caplacizumab;Drug: Corticosteroids;Biological: anti-CD20 antibody	Sanofi	NULL	Recruiting	18 Years	80 Years	All	61	Phase 3	United States;Belgium;Czechia;France;Germany;Netherlands;Spain;United Kingdom
2	EUCTR2022-001177-31-DE (EUCTR)	15/09/2022	29/06/2022	Caplacizumaband immunosuppressive therapy without first line therapeutic plasma exchange in adults w ...	An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumaband ...	Thrombotic Thrombocytopenic Purpura MedDRA version: 20.0;Level: PT;Classification code 10043648;Term ...	Trade Name: Cablivi ® Product Name: Cablivi ® Product Code: ALX0081 INN or Proposed INN: Caplacizumab Othe ...	Sanofi-Aventis Recherche & Développement	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	64	Phase 3	United States;Czechia;Greece;Spain;Austria;United Kingdom;Switzerland;Italy;France;Czech Republic;Ca ...
3	NCT05263193 (ClinicalTrials.gov)	June 8, 2022	22/2/2022	Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic ...	Retrospective Data Collection of Pediatric Patients With Immune-mediated Thrombotic Thrombocytopenic ...	Immune-mediated Thrombocytopenic Purpura	Drug: Caplacizumab	Sanofi	NULL	Completed	N/A	18 Years	All	4		France
4	NCT04720261 (ClinicalTrials.gov)	May 1, 2021	12/1/2021	Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP	Efficacy of a Personalized CaplacizumabRegimen Based on ADAMTS13 Activity Monitoring in Adult Acquir ...	Thrombotic Thrombocytopenic Purpura, Acquired	Drug: Caplacizumab	University Hospital, Rouen	NULL	Not yet recruiting	18 Years	100 Years	All	125	Phase 2	NULL
5	NCT04985318 (ClinicalTrials.gov)	March 25, 2021	21/7/2021	Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP	Retrospective Analysis of the Efficiency of Caplacizumabin the Treatment of Acquired Thrombotic Thro ...	Acquired Thrombotic Thrombocytopenic Purpura	Drug: Cablivi ®	University of Cologne	NULL	Recruiting	18 Years	N/A	All	350		Germany
6	EUCTR2020-005288-30-FR (EUCTR)	28/12/2020	06/11/2020	Efficacy of a personalized caplacizumabregimen based on ADAMTS-13 activity monitoring in adult acqui ...	Efficacy of a personalized caplacizumabregimen based on ADAMTS-13 activity monitoring in adult acqui ...	acquired thrombotic thrombocytopenic purpura MedDRA version: 20.0;Level: PT;Classification code 1004 ...	Trade Name: CABLIVI	CHU de Rouen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	125	Phase 2	France
7	NCT04074187 (ClinicalTrials.gov)	October 21, 2019	14/8/2019	A Trial of Caplacizumabin Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) ...	An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumabin Japanese Patients ...	Thrombotic Thrombocytopenic Purpura	Drug: Caplacizumab (ALX-0081);Drug: Plasma exchange (PE);Drug: Corticosteroid treatment (Methylpredni ...	Sanofi	NULL	Completed	18 Years	N/A	All	21	Phase 2/Phase 3	Japan
8	EUCTR2016-001503-23-NL (EUCTR)	05/07/2017	19/07/2017	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting			Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Repu ...
9	EUCTR2016-001503-23-DE (EUCTR)	12/04/2017	03/01/2017	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 19.1;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting			Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Hun ...
10	EUCTR2016-001503-23-FR (EUCTR)	07/02/2017	20/10/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 19.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting			Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;France;Czech Republic;Hun ...

First Previous1 2 3 4Next Last